Compare DCBO & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DCBO | DNA |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.5M | 607.1M |
| IPO Year | 2020 | N/A |
| Metric | DCBO | DNA |
|---|---|---|
| Price | $18.56 | $9.45 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 2 |
| Target Price | ★ $34.67 | $10.50 |
| AVG Volume (30 Days) | 87.0K | ★ 879.7K |
| Earning Date | 02-27-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.42 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $236,691,000.00 | $180,606,000.00 |
| Revenue This Year | $13.67 | N/A |
| Revenue Next Year | $7.43 | $3.07 |
| P/E Ratio | $25.45 | ★ N/A |
| Revenue Growth | ★ 13.16 | N/A |
| 52 Week Low | $18.11 | $5.00 |
| 52 Week High | $43.84 | $17.58 |
| Indicator | DCBO | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 26.21 | 50.60 |
| Support Level | $18.11 | $8.82 |
| Resistance Level | $19.08 | $11.10 |
| Average True Range (ATR) | 0.71 | 0.60 |
| MACD | -0.19 | 0.03 |
| Stochastic Oscillator | 8.86 | 29.39 |
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.